
Keywords: AE; adverse event; ACR; American College of Rheumatology; Apo; apolipoprotein; BID; twice daily; BP; blood pressure; CHF; congestive heart failure; CRP; C-reactive protein; csDMARD; conventional synthetic disease-modifying antirheumatic drug; CV; cardiova